BMY vs GERN
BMY: A leading biopharmaceutical innovator focused on discovering and delivering life-changing medicines to address serious illnesses globally. GERN: Geron is a commercial-stage biopharma company focused on hematologic malignancies with its first-in-class telomerase inhibitor, RYTELO.
Side-by-side fundamentals
| Metric | BMY | GERN | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $59.58 | $1.22 | |
| Market cap | $121.7B | $784M | |
| P/E as of 2026-10-08 | 13.12 | n/a | |
| Net margin | +14.6% | -77690.7% | BMY higher |
| Operating margin FY2023, SEC XBRL | n/a | -81832.9% | |
| ROE FY2025, SEC XBRL | +38.2% | -37.0% | BMY higher |
| ROA FY2025, SEC XBRL | +7.8% | -14.6% | BMY higher |
| Debt / equity as of 2026-09-03 | 1.93 | 1.14 | GERN lower |
| Revenue growth (YoY) as of 2026-09-03 | +3.1% | +24.4% | GERN higher |
| Revenue CAGR (3y) SEC XBRL | +1.4% | -2.2% | BMY higher |
| Dividend yield as of 2026-09-03 | +4.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 19 | 0 | BMY higher |
| Beta as of 2026-09-03 | 0.25 | 1.11 | |
| 1-year return as of 2026-10-08 close | +33.8% | -11.6% | BMY higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.